Vivos Inc (RDGL)

[bdvest]

Y-90
https://en.wikipedia.org/wiki/Yttrium-90

y-90 undergoes ß- decay to zirconium-90 with a half-life of 64.1 hours[4] and a decay energy of 2.28 MeV.[5] It also produces 0.01% 1.7 MeV[6] photons along the way. Interaction of the emitted electrons with matter can lead to Bremsstrahlung radiation.

Production
Yttrium-90 is a decay product of strontium-90 which makes up about 5% of the nuclear daughter isotopes when uranium is fissioned.[7][not in citation given] Yttrium-90 is produced by chemical high-purity separation from strontium-90, a fission product of uranium in nuclear reactors.[8]

Medical application
90Y plays a significant role in the treatment of hepatocellular carcinoma (HCC) and other liver cancers. Trans-arterial radioembolization is a procedure performed by interventional radiologists in which microspheres are impregnated with 90Y and injected into the arteries supplying the tumor.[9] Radioembolization with 90Y significantly prolongs time-to-progression (TTP) of HCC,[10] has a tolerable adverse event profile, and improves patient quality of life more than do similar therapies.[11]